Biofrontera - Heiße Turnaround-Spekulation (Seite 5367)

[borsalin]

Hier der Link zur deutschen Seite

http://www.ariva.de/news/PTA-News-Biofrontera-AG-Biofrontera-…

[angoli77]

Biofrontera yesterday submitted the "120-day safety update" which also includes clinical and cosmetic follow-up results of our Phase III trial for field Treatment

warum wird sowas eigentlich nicht veröffentlicht ??

[greenhorn1929]

Antwort auf Beitrag Nr.: 51.061.899 von angoli77 am 11.11.15 13:15:58

Hätte man das nicht schon Freitag oder Montag machen können? Dann wäre ich vielleicht noch bei geistiger Gesundheit :-) :-) :-)

[angoli77]

wäre sehr erfreulich wenn die BCC Studien-Daten noch in diesem Jahr kommen

[angoli77]

News

Biofrontera's business operations on track



Leverkusen, 11 November 2015 - Biofrontera AG (FSE/AIM:B8F), the biopharmaceutical company focusing on sun-induced skin cancer announces that in light of the well above average volatility of the Company's share price and increased trading volumes in recent days, that there have been no new operational developments or matters which have arisen in relation to the ongoing approval processes or other operational aspects of the Company.



Business development activities remain in accordance with previous announcements in our regular financial reports, ad hoc releases and the recently published securities prospectus.



This also applies to the US approval application for the skin-cancer drug Ameluz® in the treatment of actinic keratosis. In line with the Company's timetable, Biofrontera yesterday submitted the "120-day safety update" which also includes clinical and cosmetic follow-up results of our Phase III trial for field treatment. The clinical part of the Phase III study for the European approval process for the treatment of basal cell carcinomas is expected to be complete this month, with preliminary results currently expected to be available as planned before the end of the year.

[bruder-nikolaus]

Zum ersten Mal wieder ein zwei vorne auf der Briefseite im Orderbuch.

[Radiesel2008]

Antwort auf Beitrag Nr.: 51.061.197 von angoli77 am 11.11.15 12:06:05

Deswegen hänge ich auch in dem Unternehmen mit 4 mal soviel Kapital drin.... Da weiß man was man hat. B8F erscheint im Moment dagegen wie "der Nebel des Grauens"....

[angoli77]

C. Dünwald


Allergan Medical

Business Unit Director, Iberia

April 2008 – Heute (7 Jahre 8 Monate)

Director of Allergan Medical in Spain and Portugal
Office in Madrid

Sr. Commercial Director

Allergan Medical

2008 – 2009 (1 Jahr)



International Sales and Marketing Director
Corporacion Dermoestetica

2006 – März 2008 (2 Jahre)

Responsible for all Marketing activities in Spain, Portugal, Italy and the UK, Member of Board of Directors, participated in successful spin-off of Ultralase



Bayer HealthCare

General Manager Diagnostics

1991 – März 2006 (15 Jahre)



Bayer HealthCare

Business Manager Asia Pacific Region

2002 – 2004 (2 Jahre)

Regional Business Manager



Bayer

Strategic Planning Consultant

2000 – 2002 (2 Jahre)

[angoli77]

Antwort auf Beitrag Nr.: 51.061.251 von angoli77 am 11.11.15 12:11:55

da kann er ja auch den anstehenden Investmentkonferenzen gleich mal den Hammer rausholen

[angoli77]

C. Dünwald fängt übrigens Montag an ( habs nochmal gesucht )

Leverkusen, 22 July 2015 - Biofrontera (FSE/AIM:B8F), the biopharmaceutical company focusing on sun-induced skin cancer announces the appointment of Christoph Dünwald (47) as Chief Commercial Officer (CCO). Mr. Dünwald will lead the sales and marketing of the Group as a member of the management board, which he is envisaged to join with effect from 16 November 2015, due to an existing non-compete clause.